Transplant Center

Home
402.559.2000

Fedja  Rochling,  MD

  • Alan Langnas

    Assistant Professor of Internal Medicine-GI

  • Credentials:

    MBBCH: Royal College of Surgeons

  • Phone: 402-559-6209

  • Bio:

    Dr. Rochling has been a member of the Gastroenterology and Hepatology team at the University of Nebraska Medical Center (UNMC) since 2002. She also serves an associate member of the Eppley Cancer Center and as a staff physician in Gastroenterology and Hepatology at the Veterans Administration Medical Center in Omaha, Nebraska.

    Dr. Rochling sits on the Gastroenterology Fellowship Committee at UNMC along with the Hepatology Fellowship Committee and Consent Committee.

  • Awards and Honors:

    2005 – Top Teacher Award, UNMC Department of Internal Medicine

  • Research:

    Completed Research Support
    Rochling (PI)      07/01/05-12/31/06
    Bayer Corporation
    A Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Patients with Advanced Hepatocellular Carcinoma
    Role: PI

    Rochling (PI)       03/22/04-09/30/06
    Novartis Pharmaceuticals Corporation
    A 6-Week, Randomized, Double Blind, Placebo-Controlled, Multicenter Study, to Assess the Efficacy and Safety of Tegaserod (6 mg BID) and Placebo in Female Patients with Dyspepsia
    Role: PI

    CHTF919B2203 Rochling (PI)      03/25/04-06/30/06
    Novartis Pharmaceuticals Corporation
    A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Tegaserod Alone and in Combination with Omeprazole Given Orally in Patients Suffering from Symptomatic (non-erosive) (cont.)
    Role: PI

    CL0600-005 Gilroy (PI)                 08/31/04-10/31/08
    PAREXEL International, LLC
    A Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition (PN) Dependent Short Bowel Syndrome (SBS)
    Role: PI

    CL0600-004 DiBaise (PI)             02/02/04-10/31/08
    PAREXEL International, LLC
    A Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition (PN) Dependent Short Bowel Syndrome (SBS)
    Role: PI

    Rochling (PI)                               08/18/06-08/01/08
    Tioga Pharmaceuticals, Inc.
    A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of Asimadoline in Subjects with Irritable Bowel Syndrome
    Role: PI

  • Publications, Most Recent:

    Lymphoma and tracheoesophageal fistula: Indication for a removable esophageal stent.
    Bernal AB, Rochling FA, DiBaise JK.
    Dis Esophagus. 2005;18(1):57-9.
    PMID: 15773844 [PubMed - indexed for MEDLINE]

    Do hepatotoxicity registries have a role in health care?
    Rochling FA, Zetterman RK.
    Gastroenterology. 2008 Dec;135(6):1847-50. Epub 2008 Nov 8. No abstract available.
    PMID: 19000684 [PubMed - indexed for MEDLINE]

  • Professional Organization Memberships:

    Gastroenterology Fellowship Committee, UNMC
    Hepatology Fellowship Committee, UNMC
    Consent Committee, UNMC